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ABSTRACT 
Diet-induced Obesity Decreases Liver Iron Stores in Mice Fed Iron Deficient,  
 
Adequate, or Excessive Diets  
 
 
by 
 
 
Brett Healy, Master of Science 
Utah State University, 2013 
Major Professor: Dr. Korry J. Hintze 
Department: Nutrition, Dietetics and Food Sciences 
 
 
 Epidemiological and observational evidence suggests that obesity is 
related to poor Fe status.  To determine interactions between obesity, dietary Fe 
intake and Fe status; male, weanling C57BL/6J mice were fed either high fat 
diets to induce obesity or a standard diet for 16 weeks.  Fe concentrations of 
both the high fat or control diet (4.5 vs 3.8 kcal/g) were set at: 5, 50 or 500 mg 
Fe/kg diet.  Mice fed the high fat diets had significantly higher percentage body 
fat (17.9%) compared to mice fed control diets (5.3%, P<0.001).   Among obese 
mice, dietary Fe levels did not significantly influence body composition. 
Conversely among lean mice, mice fed the iron excessive diet had significantly 
less fat mass when compared to mice fed the iron deficient diet (P<0.05).  
Obesity and/or dietary Fe concentration did not significantly affect plasma Fe 
levels.  ANOVA analysis showed significant effects of diet-induced obesity, 
dietary Fe and an interaction between both factors on liver Fe levels (P< 0.05).  
	   iv 
Obese mice had significantly lowered liver Fe levels compared to lean cohorts 
fed the same amount of dietary Fe (P<0.05 for all comparisons).  Moreover, lean 
mice fed the Fe deficient diet (5 mg Fe/kg diet) had similar liver Fe levels (127 
mg Fe/kg ± 0.04) compared to obese mice fed the 50 mg Fe/kg diet (132 mg 
Fe/kg ± 0.05).  These data suggest that obesity, independent of dietary Fe 
intake, influences liver Fe stores. 
(31 pages) 
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PUBLIC ABSTRACT 
 
 
 Evidence from numerous studies indicates a relationship between obesity 
and low iron deficiency. To determine interactions between obesity, dietary iron 
intake and iron status; mice were fed either high fat diets to induce obesity or a 
standard diet for 16 weeks. Iron concentrations of both diets were set at 5, 50 or 
500 mg iron/kg diet. Mice red the high fat diets had a higher percentage of body 
fat when compared to mice fed standard diets. Among obese mice, dietary iron 
levels did not significantly influence body composition. Conversely among lean 
mice, mice fed the iron excessive diet had significantly less fat mass when 
compared to mice fed the iron deficient diet. Neither obesity nor iron 
concentration significantly affected plasma iron levels. Statistical analysis 
showed significant effects of diet-induced obesity, dietary iron and an interaction 
between both factors on liver iron levels. Obese mice had significant lower liver 
iron levels compared to lean cohorts fed the same amount of dietary iron. 
Further, lean mice fed the iron deficient diet had similar liver iron levels compared 
to obese mice fed the iron-sufficient diet. The study suggests that obesity, 
independent of dietary iron intake, influences liver iron stores.
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 CHAPTER I 
INTRODUCTION 
Iron Absorption, Transport, and Storage 
 Iron is an absolute requirement for life. It is involved in many important 
biochemical reactions ranging from cellular respiration to DNA synthesis. A 
healthy human body contains between 2 and 4 grams of iron with over 65% 
found in hemoglobin. Dietary iron is available in two forms, heme and nonheme. 
Heme iron is typically found in animal products while nonheme iron is found in 
plant products (1). Heme iron is absorbed at the brush border membrane of small 
intestinal cells by heme carrier protein 1 (hcp1) (1). Once inside the cell, iron is 
liberated from heme by heme-oxygenase. Once released from food components, 
nonheme iron is found as either ferric (Fe3+) or ferrous (Fe2+) iron. Ferrous iron is 
absorbed across the brush border membrane by the divalent metal transporter 1 
(DMT1) while ferric iron is reduced by duodenal cytochrome b reductase then 
transported by DMT1 (2).  
 Iron absorption is regulated by the protein hepcidin, which is released 
when iron stores are adequate or high (3). Hepcidin works by binding and 
degrading the protein ferroportin (3). Ferroportin is a basolateral membrane 
protein found in the intestine responsible for the transport of iron from the 
intestine into circulation (2). Thus, with the loss of ferroportin iron can no longer 
be transported into circulation from intestinal cells. Once absorbed, iron may 
either be transported out of the intestinal cells and into the bloodstream for use in 
body tissues, stored for future use, or used by the intestinal cell (4). Cellular iron 
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is stored primarily inside the protein ferritin, which is typically produced in liver, 
spleen, bone marrow, and intestinal cells (4). Ferritin has a sphere-like structure 
and may store thousands of iron atoms (4). Iron is stored in ferritin to prevent 
cellular damage and limit availability to bacteria (5). Unbound iron can lead to 
production of harmful free radicals that are very reactive and incur damage to 
cells (4). The main storage site for iron in the body is the liver, though a 
significant amount is also stored in the bone marrow and spleen. Once 
transported to these tissues by transferrin, iron is stored bound to ferritin (2). 
Iron Deficiency and Toxicity 
 Although necessary for sustaining life, iron’s chemical properties can also 
catalyze the formation of reactive oxygen species, which are hypothesized to be 
involved in the etiology of most common chronic diseases. Diseases attributable 
to iron toxicity are among the most common worldwide. With over 300,000 born 
each year with severe hemoglobin disorders as estimated by the World Health 
Organization (WHO) (WHO Sickle-Cell Disease and Other Hemoglobin Disorders 
Fact Sheet), sickle-cell anemia and thalassemia are among the most common 
genetically-inherited diseases. Treatment of thalassemia with regular blood 
transfusions leads to severe iron overload and toxicity. Hemochromatosis, a 
disease characterized by severe over-absorption of iron potentially leading to 
organ failure, is also one of the most commonly inherited diseases, affecting 
approximately 50 out of every 10,000 Americans. Unlike other essential metals, 
there is not a specific excretion mechanism. Therefore, iron can accumulate in 
tissues and result in toxicity.  
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 Conversely, affecting approximately 2 billion people worldwide, iron 
deficiency is the most common mineral deficiency and affects not only the health 
of individuals, but may also decrease work capacity in populations having major 
effects on the economy and country development (WHO Nutrition Deficiencies 
Fact Sheet). The WHO also estimates that 50% of pregnant women and 40% of 
preschool children are suffering from iron deficiency (WHO Nutrition Deficiencies 
Fact Sheet). Furthermore, studies have shown a link between iron deficiency and 
slow cognitive development (6-10). For example, a review conducted by McCann 
and Ames (7) showed that although test performance was poor in iron deficient 
children over the age of two test performance improved significantly after iron 
treatment. Coupled together, the potential social and economic impact of iron 
deficiency is great and stresses the need to understand the mechanisms of iron 
metabolism and absorption from the diet. 
Obesity 
 In developed countries obesity has quickly become an epidemic and for 
the first time in human history over-nutrition is a larger problem that under-
nutrition. WHO estimated that in 2008 more than 1.4 billion adults were 
overweight and at lease 500 million adults were obese. WHO projects that by 
2015, 2.3 billion adults will be overweight and 700 million will be obese. In 
addition, WHO estimates that overweight and obesity are the fifth leading risk for 
death worldwide with 44% of diabetes, 23% of ischemic heart disease and at 
lease 7% of cancer being attributable to overweight and obesity (WHO Obesity 
and Overweight Fact Sheet, May 2012).  
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Iron Status and Obesity 
 Obesity has long been known to be associated with poor iron status. 
Studies conducted as early as 1962 and 1963 showed obesity’s association with 
low iron status in adolescents (11,12). A study conducted in 2004 by Nead et al. 
(13) demonstrated the association of obesity and poor iron status. Iron status 
was defined by three factors: transferrin saturation, free erythrocyte 
protoporhpyrin levels and serum ferritin levels. The adolescent was considered 
iron deficient if two of the three values were abnormal for age and gender. 
Overweight adolescents were defined as being in the 95th percentile and above, 
at risk adolescents were between the 85th and 94th percentile and normal 
adolescents were below the 85th percentile for age and gender. The results of 
this study showed increasing prevalence of iron deficiency as weight status 
increased. Further, LeCube et al. (14) conducted a study exploring iron 
deficiency in obese postmenopausal women. Obesity in this study was defined 
as having a BMI of at least 30. Menopausal status was determined by self-report 
of discontinuation of menstruation or hysterectomy. Iron status was determined 
by measuring soluble transferrin receptor (sTfR) in the blood where high 
concentrations of sTfR indicate low iron concentrations. Results of this study 
showed that as BMI increased sTfR also increased, indicating poor iron status in 
obese post-menopausal women. Other studies have shown this association in 
children and adolescents (15,16) and adult men and women (17-20) and is and 
independent factor contributing to poor iron status (14,16,17,19). The association 
shown in postmenopausal women and adult men is particularly compelling 
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because these are two populations not typically at risk for low iron status. Obesity 
is increasingly being recognized as an inflammatory condition and adipose tissue 
as an endocrine organ. Obesity is characterized by adipocyte hypoxia resulting in 
the increased expression of hormones like interleukin-6 (IL-6), TNF-α and leptin 
in adipose tissue, which are then secreted into the bloodstream (21). Due to the 
nature of obesity and the growing epidemics that are obesity and low iron status, 
it is crucial to understand the mechanisms underlying obesity-induced iron 
deficiency. 
Hepcidin 
 Hepcidin is often referred to as the master regulator of iron homeostasis 
and its discovery is the most significant recent finding for our understanding of 
dietary iron regulation. In an effort to investigate the effects of disrupting 
upstream regulatory factor 2 (USF2) on glucose-dependent gene regulation in 
the liver, researchers Nicolas et al. (22) discovered that USF2 knockout mice 
developed severe iron overload in the liver and pancreas. Though USF2 plays no 
role in iron metabolism, hepcidin (a gene adjacent to USF2) expression was 
unintentionally disrupted and therefore implicated as a causative factor of the iron 
overload. Since then, hepcidin has been shown to play a key role in regulating 
organismal iron metabolism. Increases in hepcidin expression have been shown 
to deplete serum iron levels (23). A study conducted by Rivera et al. (23) showed 
after an injection of 50 µg of synthetic hepcidin serum iron levels in mice dropped 
more than 400% within one hour after injection and remained depressed for 48 
hours. Hepcidin has also been shown to prevent iron efflux from enterocytes and 
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macrophages (3). Hepcidin targets the cellular iron exporter ferroportin leading to 
its internalization and degradation, ultimately preventing iron export from 
hepatocytes, macrophages and enterocytes thus dropping systemic iron levels 
(3). A study conducted by Yamiji et al further showed hepcidin to decrease 
expression of the apical iron importer DMT1 (24). In the study, Caco-2 human 
intestinal cells were exposed to hepcidin for 24 hours, and iron transport proteins 
were measured (24). DMT1 mRNA decreased while ferroportin mRNA went 
unchanged, showing that hepcidin also plays a role in luminal iron absorption 
from the diet (24). It appears that hepcidin is the key signal for decreasing 
plasma iron as a host defense mechanism by limiting iron for pathogens as well 
as limiting iron efflux from enterocytes in response to dietary iron overload.  
 Hepcidin is synthesized in the liver and gene expression is increased by 
iron overload and inflammation.  To determine the effects of dietary iron on 
hepcidin expression, Nemeth et al. (25) conducted a study in which participants 
collected their first morning urine over the course of 9 days. The morning of days 
3, 4, and 5 each participant consumed a large 65 mg dose of iron (recommended 
intake for males is 9 mg/day and for women 18 mg/day). The study showed a 
dramatic increase in hepcidin expression 24 hours after the first dose of iron. 
Hepcidin expression has also been shown to decrease under conditions of 
hypoxia and anemia (3). Accordingly, hepcidin is the iron/inflammation/oxygen 
sensor that signals for decreased dietary iron uptake after iron overload, 
decreased plasma iron after inflammation and/or infection, and increased iron 
uptake during hypoxia.  
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A study conducted by Wrighting et al. found that IL-6 appears to play a 
key role in increasing hepcidin expression in response to inflammation (23). 
HepG2 cells were treated with cycloheximide, a protein translation inhibitor, in 
the presence or absence of IL-6 to determine if IL-6 would directly induce 
hepcidin transcription (26). Hepcidin expression was 5.7-fold higher in cells 
treated with IL-6 compared to the untreated control cells. Cycloheximide-free 
cells showed a 3.5-fold difference in hepcidin expression in cells treated with IL-6 
compared to cells not treated with IL-6. The results of the study showed that IL-6 
directly induces hepcidin transcription (26). Further, in a study conducted by 
Nemeth et al. (25) hepatocytes were treated for 24 hours with 100 ng/ml 
lipopolysaccharide (LPS) to induce an inflammatory response or 100 ng/ml LPS 
and IL-6 antibodies. Hepcidin expression increased 12-fold in the LPS treated 
cells while expression fell below baseline levels when cells were treated with the 
IL-6 antibody. IL-6 mediates hepcidin induction by increasing the binding of the 
transcription factor STAT3 to hepcidin promoter (26,27). This appears to explain 
how hepcidin may be signaled by inflammation and infection.  
Obesity, Inflammation, and Adipocyte Hypoxia 
Chronic inflammation is one of the hallmarks of obesity and has been 
implicated in many obesity-related problems like insulin resistance. The 
inflammatory cytokines TNF-α and IL-6 are known to reduce insulin sensitivity. 
Kahn and Flier (28) showed that chronic secretion of these cytokines is thought 
to contribute to the development of type II diabetes. A study conducted by 
Hotamisligil et al. (21) demonstrated that TNF-α mRNA was expressed 2.5-fold 
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more in obese premenopausal women when compared to lean controls. They 
also observed a positive correlation between TNF-α mRNA expression levels in 
fat tissue and the level of hyperinsulemia, an indirect measure of insulin 
resistance (21). Furthermore, weight reduction in these subjects improved insulin 
sensitivity and exhibited decreased TNF-α mRNA in fat tissue (21). Harkins et al. 
showed that obese mice (ob/ob line) have significantly higher plasma IL-6 levels 
than their lean counterparts (29). Since IL-6 expression in the liver and spleen 
were unchanged between obese and control, the difference was attributed to 
increased IL-6 expression in adipose tissue (29). These data suggest that 
adipose tissue itself plays an important role in determining plasma TNF-α and IL-
6 levels. 
 Comparing adipose tissue in obese mice with that of lean counterparts, Ye 
et al. (30) showed that adipose tissue in obese mice is considerably more 
hypoxic than adipose tissue from lean mice. Hypoxia was measured using three 
different methods. First, partial pressure of oxygen (PO2) was measured in the 
adipose tissue using an oxygen meter and probe (30). PO2 in lean mice was 
considerably higher, suggesting hypoxia in the adipose tissue (30). Second, a 
chemical probe was injected into the mice and measured using Western blotting 
(30). The probe signal was eight times greater in the obese mice, again showing 
greater hypoxia in adipose tissue from obese mice (30). Third, researchers 
measured expression of genes known to be induced by hypoxia: hypoxia-
inducible factor 1a (HIF-1a), glucose transporter 1 (GLUT-1), heme oxygenase 
(Hemox), pyruvate dehydrogenase kinase 1 (PDK1) and vascular endothelial 
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growth factor (VEGF) (30). In the obese mice, adipose tissue had increased 
expression in HIF-1a, GLUT-1, Hemox, and PDK1 compared to lean cohorts 
(30). The increases, however, were only shown in adipose tissue (30). Further, 
hypoxia increased expression of the inflammatory cytokines TNF-α, IL-1 and IL-
6. Increased expression of cytokines was also demonstrated in 3T3-L1 cells 
cultured under hypoxic conditions (1% O2) suggesting that this system is an ideal 
model to study the effects of hypoxia on adipocyte cytokine gene expression. 
The data from Ye et al. (30) suggests that the phenomenon of obesity-induced 
inflammation may result from increased secretion of inflammatory cytokines from 
hypoxic adipocytes found in deep fat pockets. 
 Another consequence of increased adiposity and adipocyte hypoxia is 
macrophage infiltration of adipose tissue. Low partial pressure of O2 in human 
adipose tissue is correlated to macrophage infiltration (31,32). Several studies 
have demonstrated that obesity in humans increases markers of adipose 
macrophage content (32,33). Macrophage infiltration of adipose tissue increases 
expression of the inflammatory cytokines TNF-α and macrophage inflammatory 
protein-1α. Macrophage infiltration of adipose tissue is increasingly being 
recognized as part of the etiology of central obesity and a chronic inflammatory 
state.  
 A study conducted by Hintze et al. (34) explored the effects of adipocyte 
hypoxia on hepatocyte hepcidin expression. Adipocytes were cultured for 24 
hours under hypoxic conditions (1% O2) or normal culture conditions (19% O2) 
and half of each were treated with LPS. Media from the adipocytes was then 
	   10 
transferred and used to treat hepatocytes. Hypoxic adipocytes had significantly 
higher IL-6 expression, similar to in-vivo findings. Results from this study showed 
significantly increased hepcidin expression in hepatocytes treated with either 
hypoxic or LPS media. Further, the STAT3 binding site, which is known to 
mediate hepcidin response to IL-6 was mutated and hepcidin promoter activity 
was tested in reporter constructs. When the STAT3 site was mutated, hepcidin 
promoter activation was significantly lower than in the non-mutated constructs 
when treated with conditioned media from hypoxic adipocytes. The data from this 
study suggests adipocyte hypoxia may increase hepcidin expression via IL-6 and 
the STAT3 promoter element and likely plays a role in obesity and poor iron 
status.  
Conclusion 
 The necessity for iron to sustain life cannot be understated. However, the 
very properties that make iron such an important building block of life also 
contribute to some of the most common chronic diseases plaguing society today. 
The growing obesity epidemic is likely contributing to growing numbers of cases 
of poor iron status and the literature has long shown this association. Adipose 
tissue is considered by many to function as an endocrine organ, secreting 
peptide hormones and inflammatory cytokines like IL-6, leptin, and TNF-α (28). 
Since adipocyte hypoxia and inflammation have been shown to be so closely 
related to obesity, a compelling case can be made that inflammation-induced 
increases in hepcidin may ultimately be a primary cause of poor iron status in 
obesity. 
11 
 There are no studies to date comparing obese mice to lean controls fed 
deficient, adequate, or excess dietary iron and very few have examined the 
effects of obesity on iron metabolism. Ye et al. showed that pockets of adipose 
tissue from obese mice are prone to hypoxia and macrophage infiltration, 
inducing the release of inflammatory cytokines such as IL-6 in the body (30). 
Further, Nemeth et al. showed that IL-6 expression in human liver cell cultures, 
mice and human volunteers induced the expression of hepcidin (25). Moreover, 
Hintze et al. demonstrated that cultured cells treated with conditioned media from 
hypoxic adipocytes had increased hepcidin expression and this increase is 
mediated through IL-6 (34). Therefore, it is likely that diet-induced obesity and 
subsequent increases in inflammation induce hepcidin expression and inhibit 
dietary iron absorption. Because obesity results in chronic inflammation including 
increased IL-6 expression, a known inducer of hepcidin, we hypothesize that 
obesity will decrease iron status in mice compared to lean controls fed the same 
amount of dietary iron. The objective of this study was to determine the effects of 
diet-induced obesity on hepcidin expression and iron status. Mice were fed either 
iron deficient (5 mg Fe/kg feed), adequate (50 mg Fe/kg feed), or excessive (500 
mg/kg feed) diets. Upon completion of the feeding trial, tissues were analyzed to 
determine hepatic iron concentration, hepatic hepcidin expression, hepatic IL-6 
expression, adipocyte hepcidin expression, and adipocyte IL-6 expression.   
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CHAPTER II 
MATERIALS AND METHODS 
Diet Formulation 
In order to determine the relationship between diet-induced obesity and 
iron status, the C57BL/6 mouse diet-induced obesity model was used 
incorporating iron deficient, adequate, or excess in the diet. Studies conducted 
by West et al. (35) and Collins et al. (36) have shown the C57BL/6 strain to be 
susceptible to diet-induced obesity and insulin resistance. A further study  
conducted by Surwit et al. (37) showed the C57BL/6 strain increased weight gain 
and inguinal and mesentery fat pad weight when fed high fat diets for 16 weeks 
compared to mice fed control diets. Following the Surwit et al. protocol male, 
weanling, C57BL/6 mice were fed either a high fat (45% energy from fat) or 
control diet (10% energy from fat). Diets were iron (FeSO4) deficient (5 mg Fe/kg 
feed), adequate (50 mg Fe/kg feed), or excessive (500 mg/kg feed). Similar iron 
concentrations (1 mg/kg, 35 mg/kg and 500 mg/kg) were used in a study 
conducted by Mazur et al. (38) to model differences in hepcidin gene expression. 
Feed intake was monitored twice weekly in order to calculate total intake and the 
mice were weighed once a week to track weight gain. Feed was monitored by 
cage, each cage containing 3-4 mice. The design was a 3X2 factorial with 10-11 
mice per treatment (Table 1). After 16 weeks exposure to their respective 
treatments, mice were euthanized by CO2 asphyxiation. Whole blood, serum, 
plasma, liver, and perigonadal white adipose tissue samples were  
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collected from the mice and flash frozen in liquid nitrogen and then stored at         
-80°C until time for tissue analysis. 
Body Composition 
 Body composition, including fat and lean mass, was determined by MRI 
after 16 weeks of feeding.  
Gene Expression 
 RNA Extraction. RNA was extracted from liver tissue using a TRIzol RNA 
isolation method. Approximately 100 mg tissue was homogenized in 1 ml TRIzol 
reagent and then left to incubate for 5 minutes to allow for the complete 
disassociation of the nucleoprotein complexes. 0.2 ml chloroform was then 
added to the solution, shaken vigorously then centrifuged at 12,000 x g for 15 
minutes at 4°C. After centrifugation, the mixture separated into a lower red-
colored organic phase and a clear, upper aqueous phase. The aqueous phase 
 
Fe Deficient Diet              
5 mg Fe/kg Feed 
Fe Adequate Diet            
50 mg Fe/kg Feed 
Fe Overload Diet            
500 mg Fe/kg Feed 
Control Non-Obese      
10% Dietary Fat 
n=11 n=10 n=11 
Diet Induced Obesity          
45% Dietary Fat 
n=11 n=11 n=11 
Table 1. Six diets differing in total fat (10% or 45%) and iron content (5, 50, or 
500 mg Fe/kg diet) were formulated and fed to male C57BL/6 mice for 16 weeks. 
Besides Fe, diets were identical for all micronutrients including Cu and Zn.	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was transferred to a new tube using a Pasteur pipette. The RNA was then 
precipitated by mixing the aqueous phase with 0.5 ml isopropanol. After 10 
minutes of incubation, samples were centrifuged for 10 minutes at 12,000 x g 
and 4°C. The supernatant was carefully removed and the pellet was washed with 
70% ethanol. The sample was again centrifuged for 2 minutes at 12,000 x g and 
4°C. The remaining ethanol was carefully removed and the pellet was left to dry 
for approximately 5 minutes. The sample was dissolved in 0.2 ml DEPC-treated 
water. Sample purity and concentration was determined by spectroscopy. RNA 
was isolated from adipose tissue using the RNeasy Minikit (Qiagen), giving more 
than adequate amounts of RNA. Concentration was determined by spectroscopy.  
 cDNA Synthesis. RNA from liver and adipose tissue was converted into 
cDNA using the High-Capacity cDNA Archive Kit (Applied Biosystems) following 
manufacturer’s specifications. Concentrations were determined by spectroscopy. 
 mRNA Quantification. mRNA concentrations of IL-6 and hepcidin was 
assessed using the TaqMan Gene Expression Assay Kit (Applied Biosystems) 
and a DNA Engine Opticon® 2 Two-Color Real-Time PCR Detection System 
(Biorad) following manufacturer’s instructions. mRNA concentrations were 
quantified using the cycles to fluorescence midpoint cycle threshold calculation 
(2-(ΔCt experimental gene-ΔCt housekeeping gene)), using β-actin as the housekeeping gene. 
 
Iron Status  
 Whole-blood hemoglobin concentration was determined by Drabkin’s 
Reagent (Sigma-Aldrich) using the method of Drabkin et al. (39). Liver and 
15 
Figure 1. Effect of diet on (A) food intake, (B) weight gain, and (C) fat mass.  
Food intake values are cage means (n=3) ± standard deviation. Weight gain and 
fat mass are mean (n=10 or 11) ± standard deviation. Significant differences 
were determined by ANOVA and Tukey’s HSD test (P<0.05). 
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16 
plasma concentrations of iron, copper, and zinc were determined by inductively 
coupled plasma atomic-emission spectrometry (ICP).  
Statistical Analysis 
 Differences in feed intake, weight gain, body composition, liver mineral 
status, hemoglobin and hepcidin and IL-6 expression were determined by 
ANOVA and Tukey’s HSD test.  
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CHAPTER III 
RESULTS AND DISCUSSION 
Diet, Weight Gain, Fat Mass  
 Mice consuming the low fat diet ultimately consumed significantly more 
feed than their obese (P=0.0359). However, consumption was not significantly 
affected by dietary iron content (Figure 1A). Further, mice consuming the high-fat 
diet gained significantly more weight than their lean counterparts (P<0.0001). 
However, weight gain was but was not affected by dietary iron content (Figure 
1B). MRI data showed mice consuming low fat diets had less fat mass when 
compared to their obese cohorts (P<0.0001). Furthermore, mice fed diets with 
lower iron content had less fat mass than their high iron counterparts (P=0.035). 
However, there was no significant interaction effect (Figure 1C).  
Liver Iron, Zinc, Copper Concentration 
 ICP analysis of liver tissue showed increased hepatic iron concentrations 
in mice consuming the low fat diet when compared to their obese cohorts 
(P<0.0001). As expected, increased hepatic iron concentration was also 
influenced by higher dietary iron (P<0.0001). Analysis further revealed a 
significant interaction between treatments (P=0.0215) (Figure 2A). Mice 
consuming high fat diets had higher hepatic copper concentrations than their 
obese cohorts (P<0.0001) while there was no significant effect of dietary iron on 
hepatic copper concentration. However, there was a significant interaction 
between treatments (P=0.0106) (Figure 2B). Obesity had a significant effect on
A 
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Figure 2. Effect of diet on (A) liver iron status, (B) liver copper status, and (C) 
liver zinc status. Values are means (n=10 or 11) ± standard deviation. Differently 
labeled columns are significantly different. Significant differences were 
determined by Student’s T-test (P<0.05).  
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Figure 3. Effect of diet on whole blood iron status. Values are means (n=10 or 
11) ± standard deviation. Main effects of obesity and iron concentration were 
determined by ANOVA (P<0.05). Post-hoc testing was determined by Tukey’s 
HSD test. 
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Figure 4. Effect of diet on relative liver hepcidin expression. Values are means 
(n=10 or 11) ± standard deviation. Differently labeled columns are significantly 
different. Main effects of obesity and iron concentration were determined by 
ANOVA (P<0.05). Post-hoc testing was determined by Tukey’s HSD test. 
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concentrations than their obese cohorts (P<0.0001). Dietary iron had no effect on 
hepatic zinc concentration and there was no significant interaction between the 
treatments (Figure 2C). 
Hemoglobin 
 Analysis of whole blood samples showed lower concentrations of 
hemoglobin among mice consuming the low fat diet when compared to their 
counterparts fed the same amount of dietary iron (P<0.0001) (Figure 3). Dietary 
iron had no significant effect on whole blood iron status and there were no 
significant interaction effects between treatments.  
Liver Hepcidin 
 Dietary fat had a significant effect on liver hepciding expression 
(P=0.0001). Mice consuming low fat diets had increased hepatic hepcidin 
expression than their lean cohorts (Figure 4). In addition, dietary iron had a 
significant effect on liver hepcidin expression (P<0.0001).  Mice consuming 
higher amounts of iron had increased liver hepcidin expression than those  
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Figure 5. Overall correlation between liver iron status and relative liver hepcidin 
expression. 
P<0.05 
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Figure 6. Effect of diet on (A) relative liver IL-6 expression, (B) relative adipose 
hepcidin expression, and (C) relative adipose IL-6 expression. Values are means 
(n=10 or 11) ± standard deviation. Main effects of obesity and iron concentration 
were determined by ANOVA (P<0.05). Post-hoc testing was determined by 
Tukey’s HSD test.	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consuming smaller amounts. Furthermore, there was a significant interaction  
effect between treatments (P=0.0197). For example, lean mice consuming higher 
amounts of iron had increased hepcidin expression when compared to obese 
mice consuming all amounts of iron. Further, lean mice consuming high amounts 
of iron showed increased hepcidin expression when compared to other lean 
mice. Moreover, Figure 5 shows a tight correlation between increased liver 
hepcidin expression and increased liver iron status (P<0.05). Taken together the 
data suggests mice may adapt under chronic inflammatory conditions and that 
liver iron stores are a more important determinant of hepcidin expression than 
obesity induced inflammation.  
Liver IL-6 
 Neither obesity nor dietary iron had an effect on liver IL-6 expression 
(Figure 6A).  
Adipose Hepcidin 
 Dietary fat content had a significant effect on adipose hepcidin espression 
(P=0.0086) (Figure 6B). Mice consuming the low fat diet had higher adipose 
hepcidin expression than their obese cohorts, consistent with liver hepcidin 
expression. However dietary iron consumption did not significantly affect adipose 
hepcidin expression and there were no interaction affects.   
Adipose IL-6 
 Obesity significanly affected adipose IL-6 expression as mice consuming 
low fat diets exhibited increased IL-6 expression than their obese counterparts.  
Mice fed low fat, iron deficient diets had increased IL-6 expression when 
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compared to mice fed the low fat, iron overload diet and high fat, iron adequate 
or overload diets (P<0.05) (Figure 6C). Further, mice fed the low fat, iron 
adequate diet had increased IL-6 expression when compared to mice fed the 
high fat, iron overload diet (P<0.05). There were no other significant differences 
between other treatments. 
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
Iron regulation is a complex process. Various diverse proteins and 
hormones contribute to the process, illustrating the importance of iron 
metabolism in biology. The discovery of hepcidin and its role in iron regulation is 
vital to our understanding of the metabolic pathways of iron. Since obesity has 
become the great epidemic of western society and iron deficiency is common 
among the obese, it is important to understand the relationship between obesity 
and iron metabolism. Understanding how this relationship works may help with 
understanding how to best help those plagued with iron deficiency and increase 
overall worldwide health. No other studies to date have systematically 
investigated the interplay between diet induced obesity, dietary iron and effects 
on iron metabolism.  
The results of this experiment support previous findings that mice with 
high liver iron stores also have high hepatic hepcidin expression (3). Conversely, 
the data does not support the hypothesis that inflammation-induced increases in 
hepcidin expression are a primary cause of poor iron status in obesity. 
Considering the pathway for the regulation of dietary iron, low iron stores would 
suggest high hepcidin expression in connection with increased amount of 
inflammatory cytokines. However, the data shows obese mice had lower hepatic 
hepcidin expression than lean mice fed the same amount of dietary iron in spite 
of increased IL-6 expression. The data was collected after an extended period of 
time on treatment and may thus show a metabolic adaptation to chronically low 
	   25 
iron stores. The data also shows that diet-induced obesity resulted in decreased 
hepatic iron stores when the mice were fed iron deficient, adequate or excessive 
diets compared to their lean counterparts fed the same amount of dietary iron, 
supporting the association shown in many different populations. Taken together, 
the data suggests inflammatory stress may be less important in long-term iron 
regulation and liver iron stores may be a more important indicator of hepcidin 
expression and when obesity decreases liver iron stores, hepcidin expression 
also decreases.  
This study has unveiled important questions in regards to obesity, 
inflammation and iron regulation that further research could help answer. To 
demonstrate the adaptation to chronic inflammation, further studies could include 
the same endpoints being measured over the same amount of time but at shorter 
intervals. This type of study would be a great indicator of any immediate effects 
and give a broader picture of obesity’s influence on iron regulation over time. 
Further, to examine how inflammation affects iron regulation IL-6 knockout mice 
could be included in the aforementioned study. Doing so would provide a more 
mechanistic understanding of obesity induced inflammation and its effects on iron 
regulation. Moreover, a human study could be carried out to see if similar results 
occur. A longitudinal study involving obese and lean participants and measuring 
amounts of IL-6, circulating hepcidin and iron status, though expensive, would 
provide excellent insight on how this regulatory process works in humans. 
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